A-1210477
CAS1668553-26-1
⚠ This product is for research use only, not for human or veterinary use.
We typically respond within 1 business day.
| CAS Number | 1372540-25-4 |
| IUPAC Name | 2-methyl-1-[[2-methyl-3-(trifluoromethyl)phenyl]methyl]-6-morpholin-4-ylbenzimidazole-4-carboxylic acid |
| Synonyms | 2-methyl-1-[[2-methyl-3-(trifluoromethyl)phenyl]methyl]-6-morpholin-4-ylbenzimidazole-4-carboxylic acid |
| Molecular Weight | 433.40 g/mol |
| Molecular Formula | C22H22F3N3O3 |
| PubChem CID | 56949517 |
| SMILES | CC1=C(C=CC=C1C(F)(F)F)CN2C(=NC3=C(C=C(C=C32)N4CCOCC4)C(=O)O)C |
| Purity | >98% |
| Shipping Condition | Shipped under ambient temperature as non-hazardous chemical. |
GSK-2636771 (CAS 1372540-25-4) is a selective PI3Kβ (phosphoinositide 3-kinase beta) inhibitor with molecular formula C₂₂H₂₂F₃N₃O₃ and molecular weight 433.40 g/mol. The compound is a benzimidazole-4-carboxylic acid derivative bearing a 2-methyl-3-(trifluoromethyl)benzyl substituent and a morpholine ring at the 6-position.
GSK-2636771 is reported to selectively inhibit the PI3Kβ isoform in an ATP-competitive manner, with substantially reduced activity against PI3Kα, PI3Kγ, and PI3Kδ. PI3Kβ plays a central role in PTEN-deficient tumor cell survival and AKT/mTOR pathway signaling, making isoform-selective inhibition of this enzyme a subject of considerable research interest in oncology.
Each batch is analyzed by HPLC and ¹H NMR, with a Certificate of Analysis provided on shipment. Available from milligram to kilogram scale, with flexible packaging to meet R&D and scale-up requirements.
All analytical documentation is provided free of charge with every order. Raw spectral data files (NMR, HPLC, LC-MS) are also available on request — just mention it in your enquiry.